Furthermore, the upregulated expression of HDAC9 in PT cells—central players in DN pathophysiology—suggests that HDAC9 inhibition may provide cell-type-specific therapeutic advantages. This evidence concerns the gene HDAC9 and liver dysplastic nodule.